Malignancy and mortality in paediatric‐onset inflammatory bowel disease: a 3‐year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN

Risk benefit strategies in managing inflammatory bowel diseases (IBD) are dependent upon understanding the risks of uncontrolled inflammation vs those of treatments. Malignancy and mortality in IBD have been associated with disease‐related inflammation and immune suppression, but data are limited due to their rare occurrence.

[1]  E. G. Nabel,et al.  National Cancer Institute , 2020, Definitions.

[2]  M. Neovius,et al.  Childhood onset inflammatory bowel disease and risk of cancer: a Swedish nationwide cohort study 1964-2014 , 2017, British Medical Journal.

[3]  S. Hutfless.  Increased risk of cancer in children with inflammatory bowel disease , 2017, British Medical Journal.

[4]  A. Griffiths,et al.  Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease. , 2017, Gastroenterology.

[5]  Eva Steliarova-Foucher,et al.  International incidence of childhood cancer, 2001–10: a population-based registry study , 2017, The Lancet. Oncology.

[6]  D. Tanyingoh,et al.  Trends in Epidemiology of Pediatric Inflammatory Bowel Disease in Canada: Distributed Network Analysis of Multiple Population-Based Provincial Health Administrative Databases , 2017, The American Journal of Gastroenterology.

[7]  K. Young,et al.  Hepatosplenic T-cell lymphoma arising in patients with immunodysregulatory disorders: a study of 7 patients who did not receive tumor necrosis factor-α inhibitor therapy and literature review. , 2017, Annals of diagnostic pathology.

[8]  P. Seksik,et al.  The effects of aminosalicylates or thiopurines on the risk of colorectal cancer in inflammatory bowel disease , 2017, Alimentary pharmacology & therapeutics.

[9]  M. Neovius,et al.  Prevalence of paediatric inflammatory bowel disease in Sweden: a nationwide population-based register study , 2017, BMC Gastroenterology.

[10]  J. Gisbert,et al.  Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[11]  G. Veres,et al.  Malignancy and Mortality in Pediatric Patients with Inflammatory Bowel Disease: A Multinational Study from the Porto Pediatric IBD Group , 2014, Inflammatory bowel diseases.

[12]  J. Ariyaratnam,et al.  Association Between Thiopurine Use and Nonmelanoma Skin Cancers in Patients With Inflammatory Bowel Disease: A Meta-Analysis , 2014, The American Journal of Gastroenterology.

[13]  A. Amiot,et al.  European evidence based consensus for endoscopy in inflammatory bowel disease. , 2013, Journal of Crohn's & colitis.

[14]  G. Veres,et al.  ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents , 2013, Journal of pediatric gastroenterology and nutrition.

[15]  L. Dauchet,et al.  Mortality and Cancer in Pediatric-Onset Inflammatory Bowel Disease: A Population-Based Study , 2013, The American Journal of Gastroenterology.

[16]  J. González,et al.  Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project , 2012, Gut.

[17]  G. Raca,et al.  &ggr;&dgr; Hepatosplenic T-Cell Lymphoma in a Pediatric Patient With Crohn’s Disease on Combined Immunosuppressive and Immunomodulator Therapy , 2012 .

[18]  David C Wilson,et al.  Pediatric modification of the Montreal classification for inflammatory bowel disease: The Paris classification , 2011, Inflammatory bowel diseases.

[19]  M. V. van Oijen,et al.  Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease , 2011, Gut.

[20]  L. Peyrin-Biroulet,et al.  Impact of azathioprine and tumour necrosis factor antagonists on the need for surgery in newly diagnosed Crohn's disease , 2011, Gut.

[21]  A. McMahon,et al.  Tumor necrosis factor alpha blockers and malignancy in children: forty-eight cases reported to the Food and Drug Administration. , 2010, Arthritis and rheumatism.

[22]  D. Patterson,et al.  Hepatosplenic T-cell lymphoma in a young man with Crohn's disease: case report and literature review. , 2010, Clinical lymphoma, myeloma & leukemia.

[23]  F. Carrat,et al.  Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study , 2009, The Lancet.

[24]  H. Drummond,et al.  Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. , 2008, Gastroenterology.

[25]  P. Lakatos,et al.  Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? , 2006, Postgraduate Medical Journal.

[26]  M. Brydolf,et al.  Incidence and prevalence of inflammatory bowel disease in children in South‐Western Sweden , 1994, Acta paediatrica.

[27]  H. Adami,et al.  Ulcerative colitis and colorectal cancer. A population-based study. , 1990, The New England journal of medicine.

[28]  M. Frisch,et al.  Trends in overall and cause-specific mortality among patients with inflammatory bowel disease from 1982 to 2010. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[29]  Subrata Ghosh,et al.  Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. , 2012, Gastroenterology.

[30]  B. Weiss,et al.  Disease Behavior in Children with Crohn’s Disease: The Effect of Disease Duration, Ethnicity, Genotype, and Phenotype , 2008, Digestive Diseases and Sciences.